BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27145235)

  • 1. Proximal location in extremity long bones is a poor prognostic factor for osteosarcoma: A retrospective cohort study of 153 patients.
    Cates JM; Schoenecker JG
    Acta Oncol; 2016 Aug; 55(8):1036-9. PubMed ID: 27145235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations.
    Cho WH; Song WS; Jeon DG; Kong CB; Kim MS; Lee JA; Yoo JY; Kim JD; Lee SY
    Ann Surg Oncol; 2010 Mar; 17(3):702-8. PubMed ID: 19921336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
    Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
    Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma.
    Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
    Ann Oncol; 2009 May; 20(5):955-60. PubMed ID: 19153123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting Surgical Resection Margin Status for Osteosarcoma: Comparison of the AJCC, MSTS, and Margin Distance Methods.
    Cates JM
    Am J Surg Pathol; 2017 May; 41(5):633-642. PubMed ID: 28125453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients.
    Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
    J Surg Oncol; 2008 Apr; 97(5):456-61. PubMed ID: 18270971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous necrosis and additional tumor necrosis induced by preoperative chemotherapy for osteosarcoma: a case-control study.
    Song WS; Jeon DG; Cho WH; Kong CB; Cho SH; Lee SY; Lee SY
    J Orthop Sci; 2015 Jan; 20(1):174-9. PubMed ID: 25355661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post operative infection and increased survival in osteosarcoma patients: are they associated?
    Jeys LM; Grimer RJ; Carter SR; Tillman RM; Abudu A
    Ann Surg Oncol; 2007 Oct; 14(10):2887-95. PubMed ID: 17653803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The extremity localized classic osteosarcomas have better survival than the axial non-classics.
    Lin L; Deng S; Zhang F; Liang Y; Huang Z
    World J Surg Oncol; 2018 Feb; 16(1):39. PubMed ID: 29471883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.
    Bielack SS; Kempf-Bielack B; Delling G; Exner GU; Flege S; Helmke K; Kotz R; Salzer-Kuntschik M; Werner M; Winkelmann W; Zoubek A; Jürgens H; Winkler K
    J Clin Oncol; 2002 Feb; 20(3):776-90. PubMed ID: 11821461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
    Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins.
    Xie L; Guo W; Li Y; Ji T; Sun X
    J Surg Oncol; 2012 Dec; 106(7):820-5. PubMed ID: 22740310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pelvis and extremity osteosarcoma with similar tumor volume have an equivalent survival.
    Song WS; Cho WH; Jeon DG; Kong CB; Kim MS; Lee JA; Eid AS; Kim JD; Lee SY
    J Surg Oncol; 2010 Jun; 101(7):611-7. PubMed ID: 20461769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Impact of Proximal
    Berner K; Bruland ØS
    Anticancer Res; 2019 May; 39(5):2459-2466. PubMed ID: 31092440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant chemotherapy for osteosarcoma].
    Guo W; Yang RL; Tang XD; Tang S; Li DS; Yang Y
    Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1186-90. PubMed ID: 15387981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.
    Wang B; Tu J; Yin J; Zou C; Wang J; Huang G; Xie X; Shen J
    Oncotarget; 2015 Nov; 6(35):38348-59. PubMed ID: 26435480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.
    Whelan JS; Jinks RC; McTiernan A; Sydes MR; Hook JM; Trani L; Uscinska B; Bramwell V; Lewis IJ; Nooij MA; van Glabbeke M; Grimer RJ; Hogendoorn PC; Taminiau AH; Gelderblom H
    Ann Oncol; 2012 Jun; 23(6):1607-16. PubMed ID: 22015453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.